Ahmed Nazmy

Ahmed Nazmy

Auto-generated profile, based on publicly available information

Ahmed Nazmy

Faculty of Medicine Kafr‐Elsheikh University Kafr‐Elsheikh Egypt

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
ANAhmed Nazmy
Ahmed Nazmy
ASAhmed Sobhy
Ahmed Sobhy
AEAhmed Elshahat
Ahmed Elshahat
AAAhmed Abdelaziz
Ahmed Abdelaziz
EMEbtsam Makhlouf
Ebtsam Makhlouf
MMMamas A. Mamas
Mamas A. Mamas

25 August 2025 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
ANAhmed Nazmy
Ahmed Nazmy
MGMohamed Hesham Gamal
Mohamed Hesham Gamal
HEHesham Elharti
Hesham Elharti
ASAhmed Sobhy
Ahmed Sobhy
ASAhmed Yasser Shaban
Ahmed Yasser Shaban
Ahmed Nazmy, M.D., Mohamed Hesham Gamal, M.D., Hesham Elharti, M.D., Ahmed Sobhy, M.D., Ahmed Yasser Shaban, M.D.. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.25.056

3 September 2025 in Current Problems in Cardiology
Verified
Journal Article
Closed access
ANAhmed Nazmy
Ahmed Nazmy
ASAhmed Sobhy
Ahmed Sobhy
AEAhmed Elshahat
Ahmed Elshahat
KAKarim Atta
Karim Atta
MMMohamed R. Murad
Mohamed R. Murad
AAAhmed Abdelaziz
Ahmed Abdelaziz

9 October 2026 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Open access
PDF file
ANAhmed Nazmy
Ahmed Nazmy
AAAlaa Abdrabou Abouelmagd
Alaa Abdrabou Abouelmagd
ASAhmed Sobhy
Ahmed Sobhy
MAMennatullah Ashour
Mennatullah Ashour
HEHassan El-Shirbiny
Hassan El-Shirbiny
C Michael GibsonC Michael Gibson
C Michael Gibson
Background: Left atrial appendage occlusion (LAAO) has emerged as a non‐pharmacological alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). Following the publication of recent CHAMPION‐AF and CLOSURE‐AF trials, an updated synthesis of evidence is warranted to clarify the long‐term comparative efficacy and safety of LAAO versus OAC in patients with AF. Methods: We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) comparing LAAO with OAC in adults with AF. A comprehensive search of major databases was performed from inception to April 2026. The primary efficacy outcomes were major adverse cardiovascular events (MACE) and stroke. The primary safety outcome was non–procedure‐related bleeding. Random‐effects models were used to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). Results: Six RCTs including 7,004 patients (3,681 LAAO; 3,323 OAC) were analyzed. No statistically significant difference was observed for MACE (7.5% vs 6.9%; RR 1.03, 95% CI 0.79‐1.34) or stroke (3.7% vs 3.2%; RR 1.07, 95% CI 0.80‐1.43). LAAO was associated with a significantly lower risk of non‐procedure‐related bleeding (9.8% vs 16.7%; RR 0.63, 95% CI 0.52‐0.77), corresponding to an absolute risk reduction of 6.9% and an approximate number needed to treat of 15 based on crude pooled event rates over the observed trial follow‐up. Trial sequential analysis indicated that the accumulated evidence for MACE and stroke remained inconclusive. Comparator‐type subgroup analyses showed no significant interaction for MACE ( p = 0.67) or stroke ( p = 0.81) between contemporary predominantly‐DOAC and VKA comparator trials. Conclusions: LAAO was associated with lower non‐procedure‐related bleeding, while no statistically significant differences were observed for MACE or stroke. The available efficacy evidence remains inconclusive regarding equivalence or non‐inferiority, and larger trials are needed. These findings support individualized consideration of LAAO when the long‐term bleeding burden of anticoagulation is clinically important.

29 July 2025 in ASIDE Case Reports
Verified
Journal Article
Open access
PDF file
AEAhmed Elazab
Ahmed Elazab
ANAhmed Nazmy
Ahmed Nazmy
NANourhan Ahmed
Nourhan Ahmed
AHAhmed Hassan
Ahmed Hassan
EMErlin Marte
Erlin Marte
Nocardiosis is an uncommon opportunistic infection commonly affecting the lungs in immunocompromised individuals. We present an unusual case of disseminated nocardiosis involving the spinal cord and brain in a patient previously diagnosed with sarcoidosis and treated with glucocorticoids. We are presenting the case of a 46-year-old Caucasian male with sarcoidosis who develops pulmonary nocardiosis, with chest X-ray (CXR) revealing left lower lobe infiltrates diagnosed as community-acquired pneumonia usually caused by Nocardia, confirmed by excisional biopsy. A few days later, the disease progressed to the spinal cord, leading to an epidural abscess, and disseminated to the brain, leading to multiple ring-enhancing lesions confirmed by MR. Timely surgical intervention, such as abscess drainage, is crucial in the management of abscesses to prevent life-threatening complications and preserve neurological function. Clinicians should maintain a broad differential diagnosis when evaluating new pulmonary infiltrates in patients with sarcoidosis. Early CNS imaging should be considered in cases of severe pulmonary nocardiosis to prevent catastrophic complications.

18 May 2026 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Open access
ANAhmed Nazmy
Ahmed Nazmy
HEHassan El-Shirbiny
Hassan El-Shirbiny
AAAlaa Abdrabou Abouelmagd
Alaa Abdrabou Abouelmagd
NHNoha Hammad
Noha Hammad
SSSamar Mohamed Sadek
Samar Mohamed Sadek
PSPhilipp Sommer
Philipp Sommer
Catheter ablation is an established therapy for ventricular tachycardia (VT); however, hemodynamic instability frequently limits procedural mapping and success. Temporary mechanical circulatory support (tMCS) devices are increasingly used to maintain end‐organ perfusion during VT ablation, yet their impact on clinical outcomes remains uncertain. We aimed to evaluate the impact of tMCS on clinical outcomes and periprocedural complications in patients undergoing VT ablation. A systematic search of PubMed/MEDLINE, Scopus, Web of Science, and Cochrane CENTRAL was conducted from database inception through December 2025. We included observational studies enrolling adult patients undergoing VT ablation with tMCS, compared with VT ablation performed without MCS. Primary outcomes were all‐cause mortality, in‐hospital mortality, procedural success, VT recurrence, and major adverse cardiovascular events (MACE). Ten observational studies comprising 16,838 patients were included, of whom 1402 received tMCS. There was no significant difference in all‐cause mortality between tMCS and no‐MCS groups (RR 1.71, 95% CI 0.68 to 4.26), procedural success (RR 1.05, 95% CI 0.92 to 1.21), VT recurrence (RR 0.99, 95% CI 0.80 to 1.22), or MACE (RR = 0.79, 95% CI: 0.62 to 1.01). However, tMCS use was associated with significantly higher in‐hospital mortality (RR 7.41, 95% CI 4.77 to 11.66). The tMCS group also demonstrated increased risks of stroke, pericardial effusion or tamponade, and periprocedural complications. In non‐randomized studies, tMCS during VT ablation was not associated with improved long‐term outcomes, while higher in‐hospital mortality and complications likely reflected patient selection and timing of support rather than adverse device effects.